Chris Kourtis is on a winning streak. Here’s his next ASX pick

Chris Kourtis of Ellerston Capital thinks he’s found another winner and thinks it’s the last chance to have a bite at the cherry before the strategy plays out.

Joshua Peach

Chris Kourtis is on a winning streak. Here’s his next ASX pick

October 21, 2024
Chris Kourtis of Ellerston Capital thinks he’s found another winner and thinks it’s the last chance to have a bite at the cherry before the strategy plays out.
Read Transcript

Chris Kourtis thinks he’s found another winner.

“It’s a stock I’ve known for a long time. I’ve missed the big run over the last few years, but we’ve recently gone back in,” he tells The Australian Financial Review. “I think it’s the last chance to have a bite at the cherry before the strategy plays out.”

Chris Kourtis, portfolio manager at Ellerston Capital, is on a hot streak. Picture: Dominic Lorrimer

The Ellerston Capital portfolio manager is talking about retail giant Premier Investments. As with many of Kourtis’ investments, his decision to buy in appears at odds with the market.

Shares in the retailer sank 13 per cent last month after revealing a sales slump and plans to delay the demerger of its Smiggle and Peter Alexander businesses.

“Obviously, the market has been disappointed by their recent result,” he says. “But at the end of the day, it’s a very well-run business. The balance sheet is pristine.”

He is confident that despite the concerns floating around the market, the company can make good on its growing list of promises, including the spin-offs and a possible merger of its apparel brands with department store Myer.

“They will demerge Smiggle and Peter Alexander. That’s been pushed out, but not abandoned,” Kourtis says. “The focus now is on consummating the Myer merger with Premier’s apparel brands, and that will add value to shareholders.”

Kourtis says Premier’s large stake in ASX-listed kitchen appliances maker Breville should help abate some of the other concerns baked into the share price. “If you add up the billion-dollar Breville holding with their Myer holding, with the net cash, you’re not paying a lot for the residual businesses,” he says.

Perhaps most important for Kourtis, however, is that the company remains very much in the hands of famous merchant Solomon Lew.

“The best retailer in Australia has hands on all over those businesses. He will walk into a store on a Saturday with a baseball cap and a fake moustache, sunglasses and see how long it takes the assistant to serve him,” Kourtis says.

“I’ll back Solly all day, every day. He doesn’t miss a trick and that’s why he’s built a very successful business over 50 years.”

If his call on Premier Investments proves fruitful, it will cap an impressive string of turnaround bets by Kourtis who’s developed a reputation for calling the bottom for some of the ASX’s most notable out-of-favour companies.


Stock picking with a side of dip


When Kourtis stepped onto the stage at last year’s Sohn Hearts & Minds event in Sydney, the famed contrarian investor named ASX health-techs ResMed and CSL as his picks.

At the time, Kourtis went out on a limb, saying the concerns that weight-loss drugs such as Ozempic would reduce the need for the services offered by both companies were overblown. “Some of my best returns have come from picking a turnaround story and, like ResMed, just at that inflection point when the market’s maximum bearish,” he says.

It was a good call. While Kourtis would sell out of his CSL shares several months later, notching a decent return in the process, his Ellerston Australian Share Fund still owns ResMed. When he stepped off the Sohn stage in November last year, the shares were trading at around $20 apiece. They last traded just below $36.

In June, Kourtis made another controversial pick, telling investors in a closed-door briefing that he was backing troubled packaging giant Orora. The shares surged more than 30 per cent in the weeks following, and Kourtis sold shortly after. “It’s not cheap any more, so I’ve left the building – I only buy cheap things,” he adds.

Andrew Forrest’s Fortescue is another recent addition after the stock slumped around 30 per cent. He’s already taking some profits from the iron ore producer. “We’ve halved our position on that recent bounce up,” he says. “With resource stocks, sometimes you just got to trade them.”

The latest run of dip-buying successes has helped solidify Kourtis’ reputation as a buyer willing to step in when others shy away.

 

Value traps and falling knives


That contrarian approach can often land investors in the dreaded “value trap” when a sold-off stock looks cheap but ultimately fails to rebound – or in the case of embattled casino operator Star Entertainment, continue to dive. “The hardest thing in funds management for anyone who’s got any valuation discipline is [to] avoid the value trap.”

That’s proved the case for investors at the WAM Leaders Fund, which made a big bet on Star last year only for the stock to plummet with the casino operator nearing financial collapse in subsequent quarters.
“A lot of really smart investors have been caught with their pants down, and a lot of them will regret those decisions,” Kourtis says, adding he hasn’t owned the stock in years, last trading out when it still held a “five-handle”.

“That’s $5 not 5¢,” he says. Star’s shares last traded around 25¢.

So with the shares now in the doldrums, is the stock piquing the portfolio manager’s interest? “Would I buy it at 25¢? No – I think it could go to zero.”

He says the decision to steer clear of Star was, in part, informed by his own mistake made nearly a decade earlier, when shares in BlueScope Steel were trading at similarly cheap levels. “I caught the falling knife,” he says. “It was trading at a massive discount price to book and then suddenly they lost $500 million [in earnings]. I didn’t see that one coming and got it right between the eyes.”

He says the “painful error” cost the fund returns. Kourtis quickly sold out at around 85¢ – it would eventually decline to around 30¢.

A year on from his ResMed pick, Kourtis is preparing his next selection for the Sohn Hearts & Minds 2024 Conference in Adelaide next month. While he’s tight-lipped on his stock pick, the themes for this year’s event will explore space, artificial intelligence, geopolitics and biosciences.

The Australian Financial Review is a media partner of Sohn Hearts & Minds.

This article was originally posted by The Australian Financial Review here. 

Licensed by Copyright Agency. You must not copy this work without permission.

Disclaimer: This material has been prepared by the Australian Financial Review, published on 21 October 2024. HM1 is not responsible for the content of linked websites or content prepared by third party. The inclusion of these links and third-party content does not in any way imply any form of endorsement by HM1 of the products or services provided by persons or organisations who are responsible for the linked websites and third-party content. This information is for general information only and does not consider the objectives, financial situation or needs of any person. Before making an investment decision, you should read the relevant disclosure document (if appropriate) and seek professional advice to determine whether the investment and information is suitable for you.

Chris Kourtis thinks he’s found another winner.

“It’s a stock I’ve known for a long time. I’ve missed the big run over the last few years, but we’ve recently gone back in,” he tells The Australian Financial Review. “I think it’s the last chance to have a bite at the cherry before the strategy plays out.”

Chris Kourtis, portfolio manager at Ellerston Capital, is on a hot streak. Picture: Dominic Lorrimer

The Ellerston Capital portfolio manager is talking about retail giant Premier Investments. As with many of Kourtis’ investments, his decision to buy in appears at odds with the market.

Shares in the retailer sank 13 per cent last month after revealing a sales slump and plans to delay the demerger of its Smiggle and Peter Alexander businesses.

“Obviously, the market has been disappointed by their recent result,” he says. “But at the end of the day, it’s a very well-run business. The balance sheet is pristine.”

He is confident that despite the concerns floating around the market, the company can make good on its growing list of promises, including the spin-offs and a possible merger of its apparel brands with department store Myer.

“They will demerge Smiggle and Peter Alexander. That’s been pushed out, but not abandoned,” Kourtis says. “The focus now is on consummating the Myer merger with Premier’s apparel brands, and that will add value to shareholders.”

Kourtis says Premier’s large stake in ASX-listed kitchen appliances maker Breville should help abate some of the other concerns baked into the share price. “If you add up the billion-dollar Breville holding with their Myer holding, with the net cash, you’re not paying a lot for the residual businesses,” he says.

Perhaps most important for Kourtis, however, is that the company remains very much in the hands of famous merchant Solomon Lew.

“The best retailer in Australia has hands on all over those businesses. He will walk into a store on a Saturday with a baseball cap and a fake moustache, sunglasses and see how long it takes the assistant to serve him,” Kourtis says.

“I’ll back Solly all day, every day. He doesn’t miss a trick and that’s why he’s built a very successful business over 50 years.”

If his call on Premier Investments proves fruitful, it will cap an impressive string of turnaround bets by Kourtis who’s developed a reputation for calling the bottom for some of the ASX’s most notable out-of-favour companies.


Stock picking with a side of dip


When Kourtis stepped onto the stage at last year’s Sohn Hearts & Minds event in Sydney, the famed contrarian investor named ASX health-techs ResMed and CSL as his picks.

At the time, Kourtis went out on a limb, saying the concerns that weight-loss drugs such as Ozempic would reduce the need for the services offered by both companies were overblown. “Some of my best returns have come from picking a turnaround story and, like ResMed, just at that inflection point when the market’s maximum bearish,” he says.

It was a good call. While Kourtis would sell out of his CSL shares several months later, notching a decent return in the process, his Ellerston Australian Share Fund still owns ResMed. When he stepped off the Sohn stage in November last year, the shares were trading at around $20 apiece. They last traded just below $36.

In June, Kourtis made another controversial pick, telling investors in a closed-door briefing that he was backing troubled packaging giant Orora. The shares surged more than 30 per cent in the weeks following, and Kourtis sold shortly after. “It’s not cheap any more, so I’ve left the building – I only buy cheap things,” he adds.

Andrew Forrest’s Fortescue is another recent addition after the stock slumped around 30 per cent. He’s already taking some profits from the iron ore producer. “We’ve halved our position on that recent bounce up,” he says. “With resource stocks, sometimes you just got to trade them.”

The latest run of dip-buying successes has helped solidify Kourtis’ reputation as a buyer willing to step in when others shy away.

 

Value traps and falling knives


That contrarian approach can often land investors in the dreaded “value trap” when a sold-off stock looks cheap but ultimately fails to rebound – or in the case of embattled casino operator Star Entertainment, continue to dive. “The hardest thing in funds management for anyone who’s got any valuation discipline is [to] avoid the value trap.”

That’s proved the case for investors at the WAM Leaders Fund, which made a big bet on Star last year only for the stock to plummet with the casino operator nearing financial collapse in subsequent quarters.
“A lot of really smart investors have been caught with their pants down, and a lot of them will regret those decisions,” Kourtis says, adding he hasn’t owned the stock in years, last trading out when it still held a “five-handle”.

“That’s $5 not 5¢,” he says. Star’s shares last traded around 25¢.

So with the shares now in the doldrums, is the stock piquing the portfolio manager’s interest? “Would I buy it at 25¢? No – I think it could go to zero.”

He says the decision to steer clear of Star was, in part, informed by his own mistake made nearly a decade earlier, when shares in BlueScope Steel were trading at similarly cheap levels. “I caught the falling knife,” he says. “It was trading at a massive discount price to book and then suddenly they lost $500 million [in earnings]. I didn’t see that one coming and got it right between the eyes.”

He says the “painful error” cost the fund returns. Kourtis quickly sold out at around 85¢ – it would eventually decline to around 30¢.

A year on from his ResMed pick, Kourtis is preparing his next selection for the Sohn Hearts & Minds 2024 Conference in Adelaide next month. While he’s tight-lipped on his stock pick, the themes for this year’s event will explore space, artificial intelligence, geopolitics and biosciences.

The Australian Financial Review is a media partner of Sohn Hearts & Minds.

This article was originally posted by The Australian Financial Review here. 

Licensed by Copyright Agency. You must not copy this work without permission.

Disclaimer: This material has been prepared by the Australian Financial Review, published on 21 October 2024. HM1 is not responsible for the content of linked websites or content prepared by third party. The inclusion of these links and third-party content does not in any way imply any form of endorsement by HM1 of the products or services provided by persons or organisations who are responsible for the linked websites and third-party content. This information is for general information only and does not consider the objectives, financial situation or needs of any person. Before making an investment decision, you should read the relevant disclosure document (if appropriate) and seek professional advice to determine whether the investment and information is suitable for you.

Disclaimer: This material has been prepared by Australian Financial Review, published on Oct 21, 2024. HM1 is not responsible for the content of linked websites or content prepared by third party. The inclusion of these links and third-party content does not in any way imply any form of endorsement by HM1 of the products or services provided by persons or organisations who are responsible for the linked websites and third-party content. This information is for general information only and does not consider the objectives, financial situation or needs of any person. Before making an investment decision, you should read the relevant disclosure document (if appropriate) and seek professional advice to determine whether the investment and information is suitable for you.

facebook
linkedin
All
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Eminence Capital founder Ricky Sandler in Sydney. Picture: John Feder‍Eminence Capital founder Ricky Sandler in Sydney. Picture: John Feder‍Eminence Capital founder Ricky Sandler in Sydney. Picture: John Feder‍Eminence Capital founder Ricky Sandler in Sydney. Picture: John Feder‍
November 6, 2024

Why this New York hedge fund manager sees opportunity in European stocks

Influential New York-hedge fund manager Ricky Sandler will turn to Europe for his next stock pick.

Read More
Vihari Ross of Antipodes. Picture: Louie DouvisVihari Ross of Antipodes. Picture: Louie DouvisVihari Ross of Antipodes. Picture: Louie DouvisVihari Ross of Antipodes. Picture: Louie Douvis
November 5, 2024

Antipodes’ Ross says short-term wealth hinges on US election

The portfolio manager says defensive stocks pose a bigger risk than the magnificent seven for investors that are overexposed to the American sharemarket.

Read More
Antipodes Partners portfolio manager Vihari Ross: ‘We ask where the overvaluation is and where the opportunity is.’ Picture: John FederAntipodes Partners portfolio manager Vihari Ross: ‘We ask where the overvaluation is and where the opportunity is.’ Picture: John FederAntipodes Partners portfolio manager Vihari Ross: ‘We ask where the overvaluation is and where the opportunity is.’ Picture: John FederAntipodes Partners portfolio manager Vihari Ross: ‘We ask where the overvaluation is and where the opportunity is.’ Picture: John Feder
November 5, 2024

Concentration risk key for investors: Antipodes Partners’ Vihari Ross

The concentration risk in global stock indexes that has built up during the strong rise over the past year must now be a key consideration for global investors, according to Vihari Ross.

Read More
JO Hambro Asset Management senior portfolio manager Samir Mehta.JO Hambro Asset Management senior portfolio manager Samir Mehta.JO Hambro Asset Management senior portfolio manager Samir Mehta.JO Hambro Asset Management senior portfolio manager Samir Mehta.
November 5, 2024

The fundie betting big on China – with help from AI

Mr Mehta is sticking to his well-worn strategy: he’s hunting for companies across Asia that aren’t battling intense competition and have management teams focused on costs, cash generation and high payouts to shareholders.

Read More
Beeneet Kothari is ready to shock the Sohn Hearts & Minds event.Beeneet Kothari is ready to shock the Sohn Hearts & Minds event.Beeneet Kothari is ready to shock the Sohn Hearts & Minds event.Beeneet Kothari is ready to shock the Sohn Hearts & Minds event.
October 29, 2024

Why this fundie wants you to ‘wince’ at his stock picks

When fund managers come to pitch their favourite stock at the annual Sohn Hearts & Minds conference, there are two ways they can go: they can play it safe, or they can take a risk and shock the room.

Read More
October 27, 2024

IFM Investors’ Rikki Bannan backs small cap investments to rebound after mixed performance

IFM Investors executive director Rikki Bannan believes this year could be a good one to invest in some select small cap stocks.

Read More
October 22, 2024

Meet the 2024 Conference Managers

Following a global search, the Conference Fund Manager Selection Committee is pleased to share eleven new managers for 2024.

Read More
Ellerston Capital portfolio manager Chris Kourtis. Picture: Britta CampionEllerston Capital portfolio manager Chris Kourtis. Picture: Britta CampionEllerston Capital portfolio manager Chris Kourtis. Picture: Britta CampionEllerston Capital portfolio manager Chris Kourtis. Picture: Britta Campion
October 21, 2024

Why Ellerston Capital’s Chris Kourtis plans to back a ‘hated’ stock

Chris Kourtis of Ellerston Capital plans to tip one of the “most hated” stocks in Australia when he presents at the 2024 Sohn Hearts & Minds Conference.

Read More
 ‘We’re riding a wave which started (with) the first silicon chips,’ Alex Pollak says. Picture: Britta Campion ‘We’re riding a wave which started (with) the first silicon chips,’ Alex Pollak says. Picture: Britta Campion ‘We’re riding a wave which started (with) the first silicon chips,’ Alex Pollak says. Picture: Britta Campion ‘We’re riding a wave which started (with) the first silicon chips,’ Alex Pollak says. Picture: Britta Campion
October 14, 2024

Alex Pollak champions rewards of disruptive investment

Alex Pollak’s funds management company Loftus Peak rode the Nvidia wave and he is now looking at more opportunities in disruptive industry stocks.

Read More
October 8, 2024

Sumit Gautam - Why AI won't deliver in 2025 | Scalar Gauge

Sumit Gautam is the Founder of Scalar Gauge and speaks with Equity Mates ahead of his appearance at the Sohn Hearts & Minds conference.

Read More
September 30, 2024

Missed out on Nvidia and Ozempic? This fundie says it’s never too late

Northcape Capital’s Fleur Wright is still kicking herself for not owning market darlings Nvidia and Novo Nordisk, the maker of the weight loss wonder drug Ozempic, before shares of those companies rocketed in 2023.

Read More
September 23, 2024

Scalar Gauge Fund founder Sumit Gautam cautious about over-hyped AI

Tech investor Sumit Gautam carefully avoids the word bubble when describing the investor frenzy surrounding the rise of artificial intelligence, but warns there are dangers of getting caught up in the hype.

Read More
September 9, 2024

The Wellcome Trust’s Nick Moakes made a 100-year bet. It’s paying off

Chief Investment Officer, Nick Moakes raised almost $3 billion at ultra-low rates. Sometimes the long view can be the most profitable.

Read More
Wellcome Trust chief investment officer Nicholas Moakes. Picture: Steven PocockWellcome Trust chief investment officer Nicholas Moakes. Picture: Steven PocockWellcome Trust chief investment officer Nicholas Moakes. Picture: Steven PocockWellcome Trust chief investment officer Nicholas Moakes. Picture: Steven Pocock
September 5, 2024

Honesty the only policy that matters, says Wellcome Trust’s Nicholas Moakes

The chief investment officer of the London-based $71bn Wellcome Trust, Nick Moakes, has a simple rule for the trust’s investment team: “Never invest with anyone who is or has been or should have been in prison.”

Read More
September 5, 2024

Why Howard Marks says you’re making a big mistake

Howard Marks says investors must ignore manic depressive markets and focus on the bigger picture. Rates will be higher for longer and that will bring pain – and opportunity.

Read More
December 10, 2024

Professor Jane Butler: Sparking Hope for Spinal Cord Injuries

In this episode of the Hearts & Minds Podcast, we sit down with Professor Jane Butler to discuss her groundbreaking research into spinal cord injuries.

Read More
impact-podcasts
September 24, 2024

Asian Market Potential with Tom Naughton of Prusik

CIO Charlie Lanchester sits down with Tom Naughton, CIO of Prusik Investment Mgmt. Tom shares his investment philosophy, the opportunities and challenges in Asian markets, and how his 2023 conference stock pick, Swire Pacific (0019.HK), delivered an impressive 30% return.

Read More
investing
September 4, 2024

Building Hearts and Minds with Co-Founders Matthew Grounds and Guy Fowler

In this episode, co-founders Matthew Grounds AM and Guy Fowler OAM discuss their journey in building Hearts & Minds and its philanthropic model that has donated over $70 million to medical research.

Read More
investing
June 25, 2024

Navigating the Resource Sector with Jeremy Bond of Terra Capital

In this episode, we chat with Jeremy Bond, Founder of Terra Capital and HM1 Conference Fund Manager. Tune in for insights into the world of resource investments and the exciting opportunities that lie ahead.

Read More
investing
June 11, 2024

Prof. Nadia Badawi on Cerebral Palsy Breakthroughs and Neonatal Care

Dive deep into the groundbreaking work of Professor Nadia Badawi, an internationally recognised neonatologist and expert in Cerebral Palsy.

Read More
impact-podcasts
May 28, 2024

Investment Insights: Rikki Bannan on Top Picks and Trends

Join us for an engaging episode featuring Rikki Bannan, Portfolio Manager of IFM Investors and HM1 Conference Fund Manager. This episode explores Rikki's career journey, investment strategies, and her 2023 conference stock pick, Telix Pharmaceuticals (ASX.TLX).

Read More
investing
December 6, 2023

Peter Cooper talks building and instilling a culture of humility and excellence

In this episode, our guest is the renowned investor, Peter Cooper, founder and Chief Investment Officer of Cooper Investors (Core Fund Manager). A founding supporter of Hearts and Minds, Peter is a staunch advocate of our model and its philanthropic purpose, actively engaging in every facet of Hearts and Minds.

Read More
investing
November 28, 2023

Jun Bei Liu on her high conviction investment strategy

In this episode, HM1 Chief Investment Officer Charlie Lanchester is joined by Jun Bei Liu. Jun Bei is the Portfolio Manager of Tribeca’s Alpha Plus Fund and since taking over managing the Fund, she has quadrupled AUM.

Read More
investing
November 21, 2023

The world of rare genetic disease research

In this episode, we speak to Associate Professor Gina Ravenscroft. Gina is an Associate Professor in Neurogenetics at the Harry Perkins Institute of Medical Research in Perth. Her research interests are in rare genetic diseases, with a particular focus on neurogenetic diseases in babies and children.

Read More
impact-podcasts
November 14, 2023

Learn what makes a high conviction investment and how to avoid short-term noise

In this episode, our Core Fund Manager Magellan shares how they select top stocks for the HM1 portfolio.

Read More
investing
November 7, 2023

Delve into the world of kids critical care and trauma research

In thie episode, we are joined by Dr. Marino Festa, or Rino for short. He is the Medical Director of NSW Kids ECMO Referral Service and a senior specialist in Paediatric Intensive Care at Children’s Hospital at Westmead.

Read More
impact-podcasts
October 31, 2023

Where Regal's Phil King is searching for opportunities

HM1's CIO, Charlie Lanchester, talks to Phil King of Regal Funds about his passion for stocks, his ongoing search for opportunities, and some of the sectors he’s excited by right now. Phil King of Regal Funds, has been a tremendous supporter of Hearts & Minds since the beginning.

Read More
investing
October 24, 2023

Preventing recurrent miscarriages and birth defects

In this episode, CEO Paul Rayson is joined by renowned biomedical researcher Professor Sally Dunwoodie. Prof. Dunwoodie's groundbreaking work has revolutionised clinical practices and enabled genetic diagnostic tests worldwide. In 2017, her team achieved a double breakthrough with the potential to prevent recurrent miscarriages and various birth defects.

Read More
impact-podcasts
October 17, 2023

Nick Griffin on how he finds global winners

In this episode, CIO Charlie Lanchester chats with Nick Griffin, the founding partner and CIO of Munro Partners, one of HM1's Core Fund Managers. They go over his career to date, reflect on the lessons he’s learned, and trace the decisions that led to him starting Munro.

Read More
investing
October 10, 2023

How A/Prof Matt Call is teaching our body to kill cancer

In this episode, CEO Paul Rayson is joined by WEHI’s Associate Professor Matt Call to talk about his incredible research. Matt’s team teaches and trains the body's own immune cells to target and kill cancer cells.

Read More
impact-podcasts

No results found.

Please try a different search keyword or filter.